Wedbush Rates Rocket Pharmaceuticals Outperform with $32 Target
Wedbush initiates coverage on Rocket Pharmaceuticals (RCKT) with an Outperform rating and a $32 price target, signaling strong growth potential.
Topic
RCKT
A collection of 1 issue